This screening procedure code requires a diagnosis code of V76.44 that must appear on the claim form. If the patient has symptoms of prostate carcinoma along with the BPH, such as hematuria, nocturia, urinary frequency, and slow stream, a diagnostic PSA can be covered.
Symptoms include:
Specimen Required
Elevated prostate specific antigen [PSA]
*October 2017 Changes. ICD-10-CM Version – Red. ... Fu Associates, Ltd. ... 190.31 - Prostate Specific Antigen. ... Total PSA. ... Prostate Specific Antigen (PSA), a tumor marker for adenocarcinoma of the prostate, can predict residual tumor in the post-operative phase of prostate cancer. ... © ... Code. ... ICD-10-CM Codes Covered by Medicare Program.More items...
PSA when used in conjunction with other prostate cancer tests, such as digital rectal examination, may assist in the decision making process for diagnosing prostate cancer. PSA also, serves as a marker in following the progress of most prostate tumors once a diagnosis has been established.
Besides cancer, other conditions that can raise PSA levels include an enlarged prostate (also known as benign prostatic hyperplasia or BPH ) and an inflamed or infected prostate (prostatitis). Also, PSA levels normally increase with age.
Elevated prostate-specific antigen (PSA) levels can be a sign of prostate cancer. It can also indicate noncancerous problems such as prostate enlargement and inflammation. Your healthcare provider will work with you to figure out the next steps if you have a high PSA level.
Some payers, including Medicare, have different coding requirements for screening and diagnostic PSA tests. For a Medicare patient, report a screening PSA with G0103 Prostate cancer screening; prostate specific antigen test (PSA) and a diagnostic PSA with one of the following three codes (based on the type of test): ...
For a screening test for a patient with no signs or symptoms of disease, use diagnosis code Z12.5 Encounter for screening for malignant neoplasm of prostate. If you report another diagnosis code with G0103, Medicare will not pay for it. You must use a screening diagnosis with a screening CPT® code.
Or if the urologist only notes signs and symptoms, codes such as R39.11 Hesitancy of micturition may apply. Medicare will consider many diagnosis codes indicating urological signs or symptoms as payable for PSA determinations, such as: This, of course, is a short list.
Prostate specific antigen (PSA) screenings are commonplace in most urology practices, which means if you don’t have your procedure and diagnosis coding straight, you may face high denial rates and possibly significant revenue loss. Avoid those pitfalls with these three tips.
Once you decide on the codes , there’s one more point to check before submitting the claim: Payers have tight restrictions on the frequency for which they will pay for PSA tests.
You should not need modifier 25 Significant, separately identifiable evaluation and management service by the same physician or other qualified health care professional on the same day of the procedure or other service on the E/M service, as a global period does not apply to the PSA laboratory test.
If the urologist performs a separate evaluation and management (E/M) service during the same encounter as the PSA test, you should be able to separately report the PSA test code and the appropriate E/M code (based on the documented level of service).